您当前的位置:  产品信息 > bioGenous(伯桢生物)
  • bioGenous™ 人脑类器官(扩增型)培养试剂盒是一种用于培养人脑类器官的无血清培养基。在该扩增培养基中,人脑组织可在体外条件下自我组装形成类器官,成功再现体内细胞异质性及复杂组织结构的关键特征。这些类器官具备长期扩增的能力,该过程高度依赖于原始组织结构的完整性。这种结构的保留有助于构建类似天然的细胞外基质微环境,从而为类器官的持续增殖提供关键支持。
  • bioGenous™ 人脑类器官(分化型)培养试剂盒是一种用于人脑类器官(hFBs)的无血清培养基。在人脑类器官扩增培养基中,hFBs 主要由神经干细胞组成,其特征是表达 Sox2 等标志物。当将扩增培养基更换为分化培养基后,hFBs 可分化为成熟的神经元细胞,并表达特定标志物,包括 Gfap、Map2、Cux1 和 Dcx。
  • bioGenous™ 人宫颈(鳞状上皮)类器官培养试剂盒是一种专为从鳞状上皮细胞来源建立人宫颈类器官而开发的无血清培养基。该类器官能够重现宫颈外口鳞状上皮的组织结构与细胞组成,并展现出复层鳞状上皮的典型特征,包括自我更新能力及多层结构。
  • bioGenous™ 人气道类器官(分化型)培养试剂盒是一种专为分化人气道干细胞来源的人气道类器官(hAOs)而设计的无血清培养基。在分化条件下培养 10–14 天后,气道类器官可形成清晰的管腔结构,显微镜下可观察到明显的纤毛搏动或分泌物积聚现象。分化的 hAOs 展现出成熟气道上皮的关键结构与功能特征
  • bioGenous™ 人气管类器官培养试剂盒是一种无血清培养基,专用于培养源自人气管干细胞的人气管类器官(hAOs)。​人气管类器官包含基底细胞(KRT5+)、气道上皮细胞(KRT8+)和纤毛细胞(FOXJ1+),因此在组织结构、细胞类型组成及自我更新动态方面展现出气管上皮的典型特征。hAOs 的多功能性使其具备广泛应用潜力,因此在研究气道稳态与疾病方面具有广阔前景。
  • bioGenous™ 小鼠结肠类器官培养试剂盒是一种专为小鼠结肠类器官原代培养与分化设计的无血清培养基。在原代培养阶段,类器官主要由结肠干细胞(LGR5+)和前体细胞构成。当进入分化阶段后,小鼠结肠类器官还将包含结肠吸收性上皮细胞(VILL+)和杯状细胞(MUC2+)。
  • A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively
  • SB202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits[1][2]. SB202190 induces autophagy[3].
  • Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC50 of 41 nM and an EC50 of 0.5 μM for type I adenylyl cyclase[1]. Forskolin is also an inducer of intracellular cAMP formation[2]. Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR[3]. Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy.
  • DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment,